CYCLIZINE LACTATE

Posology For the prevention of postoperative nausea and vomiting, administer the first dose by slow intravenous injection 20 minutes before the anticipated end of surgery. Adults 50 mg intramuscularly or intravenously up to three times daily.

When used intravenously, Cyclizine Lactate 50mg/ml Injection should be injected slowly into the bloodstream, with only minimal withdrawal of blood into the syringe. For the prevention of postoperative nausea and vomiting, administer the first dose by slow intravenous injection 20 minutes before the anticipated end of surgery.

Cyclizine given intravenously, in half the recommended dose, increases the lower oesophageal sphincter tone and thereby reduces the hazard of regurgitation and aspiration of gastric contents if given to patients, undergoing emergency surgery, before induction of general anaesthesia.

Older people There have been no specific studies of Cyclizine Lactate 50mg/ml Injection in the elderly. Experience has indicated that normal adult dosage is appropriate. Paediatric population Not licensed for use in children. Method of Administration Intramuscularly or intravenously.

Blood and lymphatic system disorders Agranulocytosis, leucopenia, haemolytic anaemia, thrombocytopenia. 4). Eye disorders Blurred vision, oculogyric crisis. Gastrointestinal system disorders Dryness of the mouth, nose and throat, constipation, increased gastric reflux, nausea, vomiting, diarrhoea, stomach pain, loss of appetite.

General disorders and administration site conditions Asthenia. Injection site reactions including vein tracking, erythema, pain, thrombophlebitis and blisters. A sensation of heaviness, chills, and pruritus have been reported rarely.

Anaphylaxis has been recorded following intravenous administration of cyclizine co- administered with propanidid in the same syringe. 4), hypersensitivity hepatitis, cholestatic jaundice and cholestatic hepatitis have occurred in association with cyclizine.

Immune system disorders Hypersensitivity reactions, including anaphylaxis have occurred. Musculoskeletal and connective tissue disorders Twitching, muscle spasms Nervous system disorders Effects on the central nervous system have been reported with cyclizine these include somnolence, drowsiness, incoordination, headache, dystonia, dyskinesia, extrapyramidal motor disturbances, tremor, restless leg syndrome, convulsions, dizziness, decreased consciousness, transient speech disorders, paraesthesia, paralysis* and generalised chorea.

*Case reports of paralysis have been received in patients using intravenous cyclizine. Some of the patients mentioned in these case reports had an underlying neuromuscular disorder. 4). Ear and labyrinth disorders Tinnitus. There have been rare case reports of patients experiencing depressed levels of consciousness/loss of consciousness.

Psychiatric disorders Disorientation, restlessness or agitation, nervousness, euphoria, insomnia and auditory and visual hallucinations have been reported, particularly when dosage recommendations have been exceeded. Renal and urinary disorders Urinary retention Respiratory, thoracic and mediastinal disorders Bronchospasm, apnoea Skin and subcutaneous tissue disorders Urticaria, pruritus, drug rash, angioedema, allergic skin reactions, fixed drug eruption, photosensitivity.

Vascular disorders Hypertension, hypotension Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

As with other anticholinergic agents, Cyclizine Lactate 50mg/ml Injection may precipitate incipient glaucoma and it should be used with caution and appropriate monitoring in patients with glaucoma, urinary retention, obstructive disease of the gastrointestinal tract, hepatic disease, pheochromocytoma, hypertension, epilepsy and in males with possible prostatic hypertrophy.

Cyclizine Lactate 50mg/ml Injection may have a hypotensive effect. Cyclizine should be used with caution in patients with severe heart failure or acute myocardial infarction. In such patients, cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure and pulmonary wedge pressure.

Cyclizine should be avoided in porphyria. There have been reports of abuse of cyclizine, either oral or intravenous, for its euphoric or hallucinatory effects. 5). Case reports of paralysis have been received in patients using intravenous cyclizine.

Some of the patients mentioned in these case reports had an underlying neuromuscular disorder. Thus intravenous cyclizine, should be used with caution in all patients and with particular care in patients with underlying neuromuscular disorders.

1. Cyclizine Lactate 50mg/ml Injection is contraindicated in the presence of acute alcohol intoxication. The anti-emetic properties of cyclizine may increase the toxicity of alcohol.